208 related articles for article (PubMed ID: 35388215)
1. Basis of narrow-spectrum activity of fidaxomicin on Clostridioides difficile.
Cao X; Boyaci H; Chen J; Bao Y; Landick R; Campbell EA
Nature; 2022 Apr; 604(7906):541-545. PubMed ID: 35388215
[TBL] [Abstract][Full Text] [Related]
2. A roadmap for designing narrow-spectrum antibiotics targeting bacterial pathogens.
Cao X; Landick R; Campbell EA
Microb Cell; 2022 Jul; 9(7):136-138. PubMed ID: 35855392
[No Abstract] [Full Text] [Related]
3. Fidaxomicin for the treatment of
Skinner AM; Scardina T; Kociolek LK
Future Microbiol; 2020 Jul; 15(11):967-979. PubMed ID: 32715754
[TBL] [Abstract][Full Text] [Related]
4. The gut microbiome diversity of Clostridioides difficile-inoculated mice treated with vancomycin and fidaxomicin.
Yamaguchi T; Konishi H; Aoki K; Ishii Y; Chono K; Tateda K
J Infect Chemother; 2020 May; 26(5):483-491. PubMed ID: 32165071
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effect of fidaxomicin on biofilm formation in Clostridioides difficile.
Hamada M; Yamaguchi T; Ishii Y; Chono K; Tateda K
J Infect Chemother; 2020 Jul; 26(7):685-692. PubMed ID: 32224190
[TBL] [Abstract][Full Text] [Related]
6. Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile.
Collins DA; Riley TV
Lett Appl Microbiol; 2022 Sep; 75(3):526-536. PubMed ID: 35119124
[TBL] [Abstract][Full Text] [Related]
7. Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains of
Bassères E; Eubank TA; Begum K; Alam MJ; Jo J; Le TM; Lancaster CK; Gonzales-Luna AJ; Garey KW
Antimicrob Agents Chemother; 2024 Mar; 68(3):e0162123. PubMed ID: 38364016
[TBL] [Abstract][Full Text] [Related]
8. Comparison of fidaxomicin, thuricin CD, vancomycin and nisin highlights the narrow spectrum nature of thuricin CD.
Walsh L; Lavelle A; O'Connor PM; Hill C; Ross RP
Gut Microbes; 2024; 16(1):2342583. PubMed ID: 38722061
[TBL] [Abstract][Full Text] [Related]
9. [Antimicrobial profile and clinical evidence of fidaxomicin (Dafclir
Takeda S; Miki T
Nihon Yakurigaku Zasshi; 2019; 154(4):217-229. PubMed ID: 31597902
[TBL] [Abstract][Full Text] [Related]
10. Fecal pharmacokinetics/pharmacodynamics characteristics of fidaxomicin and vancomycin against Clostridioides difficile infection elucidated by in vivo feces-based infectious evaluation models.
Tashiro S; Taguchi K; Enoki Y; Matsumoto K
Clin Microbiol Infect; 2023 May; 29(5):616-622. PubMed ID: 36574949
[TBL] [Abstract][Full Text] [Related]
11. A Tapered-pulsed Fidaxomicin Regimen Following Treatment in Patients With Multiple Clostridioides difficile Infection Recurrences.
Skinner AM; Tan X; Sirbu BD; Danziger LH; Gerding DN; Johnson S
Clin Infect Dis; 2021 Sep; 73(6):1107-1109. PubMed ID: 33714998
[TBL] [Abstract][Full Text] [Related]
12. Successful Fidaxomicin Hospital Discharges of Adult Patients With Clostridioides difficile Infections Post-2021 Guidelines: Are Economic Barriers Finally Coming Down?
Fang N; Ha D; Dong K; Leung T; Lee S; Holubar M; Meng L
Clin Infect Dis; 2022 Aug; 75(3):519-521. PubMed ID: 34971358
[TBL] [Abstract][Full Text] [Related]
13. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study.
Polivkova S; Krutova M; Capek V; Sykorova B; Benes J
Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906
[TBL] [Abstract][Full Text] [Related]
14. Fidaxomicin inhibits spore production in Clostridium difficile.
Babakhani F; Bouillaut L; Gomez A; Sears P; Nguyen L; Sonenshein AL
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S162-9. PubMed ID: 22752866
[TBL] [Abstract][Full Text] [Related]
15. Clostridioides difficile infection: are the three currently used antibiotic treatment options equal from pharmacological and microbiological points of view?
Krutova M; Wilcox M; Kuijper E
Int J Infect Dis; 2022 Nov; 124():118-123. PubMed ID: 36155825
[TBL] [Abstract][Full Text] [Related]
16. Fidaxomicin compared with vancomycin and metronidazole for the treatment of Clostridioides (Clostridium) difficile infection: A network meta-analysis.
Okumura H; Fukushima A; Taieb V; Shoji S; English M
J Infect Chemother; 2020 Jan; 26(1):43-50. PubMed ID: 31624029
[TBL] [Abstract][Full Text] [Related]
17. Impact of Oral Metronidazole, Vancomycin, and Fidaxomicin on Host Shedding and Environmental Contamination With Clostridioides difficile.
Turner NA; Warren BG; Gergen-Teague MF; Addison RM; Addison B; Rutala WA; Weber DJ; Sexton DJ; Anderson DJ
Clin Infect Dis; 2022 Mar; 74(4):648-656. PubMed ID: 34017999
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides (Clostridium) difficile Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE).
Wolf J; Kalocsai K; Fortuny C; Lazar S; Bosis S; Korczowski B; Petit A; Bradford D; Croos-Dabrera R; Incera E; Melis J; van Maanen R
Clin Infect Dis; 2020 Dec; 71(10):2581-2588. PubMed ID: 31773143
[TBL] [Abstract][Full Text] [Related]
19. The development of live biotherapeutics against
Zhang Y; Saint Fleur A; Feng H
Gut Microbes; 2022; 14(1):2052698. PubMed ID: 35319337
[No Abstract] [Full Text] [Related]
20. Inhibition of spores to prevent the recurrence of Clostridioides difficile infection - A possibility or an improbability?
Chiu CW; Tsai PJ; Lee CC; Ko WC; Hung YP
J Microbiol Immunol Infect; 2021 Dec; 54(6):1011-1017. PubMed ID: 34229970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
